Stacie Jones
Concepts (421)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Food Hypersensitivity | 43 | 2024 | 100 | 9.800 |
Why?
| | Peanut Hypersensitivity | 51 | 2025 | 92 | 8.860 |
Why?
| | Desensitization, Immunologic | 49 | 2025 | 108 | 8.570 |
Why?
| | Allergens | 54 | 2025 | 140 | 6.860 |
Why?
| | Egg Hypersensitivity | 16 | 2021 | 27 | 2.290 |
Why?
| | Anaphylaxis | 15 | 2024 | 69 | 2.100 |
Why?
| | Immunoglobulin E | 31 | 2025 | 92 | 2.070 |
Why?
| | Administration, Oral | 38 | 2025 | 455 | 1.740 |
Why?
| | Child | 78 | 2025 | 7194 | 1.660 |
Why?
| | Child, Preschool | 60 | 2025 | 4046 | 1.620 |
Why?
| | Immune Tolerance | 16 | 2022 | 91 | 1.540 |
Why?
| | Asthma | 11 | 2019 | 313 | 1.530 |
Why?
| | Hypersensitivity | 4 | 2023 | 80 | 1.380 |
Why?
| | Food Supply | 2 | 2023 | 92 | 1.330 |
Why?
| | Immunotherapy | 10 | 2024 | 251 | 1.260 |
Why?
| | Humans | 140 | 2025 | 52441 | 1.210 |
Why?
| | Eosinophilic Esophagitis | 5 | 2024 | 43 | 1.150 |
Why?
| | Adolescent | 48 | 2024 | 6713 | 1.140 |
Why?
| | Double-Blind Method | 22 | 2025 | 726 | 1.080 |
Why?
| | Epinephrine | 10 | 2022 | 92 | 0.980 |
Why?
| | Nuts | 3 | 2022 | 8 | 0.830 |
Why?
| | Male | 70 | 2025 | 26874 | 0.830 |
Why?
| | Patient Advocacy | 2 | 2013 | 17 | 0.800 |
Why?
| | Skin Tests | 17 | 2019 | 59 | 0.790 |
Why?
| | Infant | 37 | 2025 | 3709 | 0.790 |
Why?
| | Eosinophils | 4 | 2024 | 39 | 0.780 |
Why?
| | Female | 69 | 2025 | 28277 | 0.780 |
Why?
| | Health Education | 2 | 2013 | 157 | 0.720 |
Why?
| | Allergy and Immunology | 3 | 2018 | 19 | 0.690 |
Why?
| | Patient Education as Topic | 3 | 2017 | 317 | 0.680 |
Why?
| | Treatment Outcome | 25 | 2025 | 5508 | 0.670 |
Why?
| | Transdermal Patch | 2 | 2019 | 3 | 0.670 |
Why?
| | Plant Proteins | 7 | 2025 | 68 | 0.650 |
Why?
| | Esophagus | 2 | 2018 | 84 | 0.650 |
Why?
| | Milk Hypersensitivity | 6 | 2024 | 19 | 0.610 |
Why?
| | School Nursing | 2 | 2010 | 9 | 0.580 |
Why?
| | Arkansas | 13 | 2019 | 2013 | 0.550 |
Why?
| | Egg Proteins | 6 | 2019 | 18 | 0.530 |
Why?
| | Antigens, Plant | 6 | 2025 | 16 | 0.530 |
Why?
| | Immunoglobulin G | 13 | 2022 | 193 | 0.520 |
Why?
| | Health Literacy | 1 | 2019 | 131 | 0.520 |
Why?
| | Sinusitis | 2 | 2007 | 42 | 0.500 |
Why?
| | T-Lymphocytes, Regulatory | 5 | 2022 | 81 | 0.490 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 12 | 2018 | 19 | 0.470 |
Why?
| | Environmental Exposure | 4 | 2017 | 225 | 0.430 |
Why?
| | Rural Population | 3 | 2018 | 587 | 0.420 |
Why?
| | Administration, Cutaneous | 6 | 2025 | 53 | 0.410 |
Why?
| | Adult | 24 | 2024 | 14205 | 0.410 |
Why?
| | Follow-Up Studies | 11 | 2021 | 2294 | 0.410 |
Why?
| | Risk Factors | 13 | 2019 | 3971 | 0.410 |
Why?
| | Practice Guidelines as Topic | 6 | 2017 | 498 | 0.390 |
Why?
| | Dermatitis, Atopic | 7 | 2016 | 39 | 0.390 |
Why?
| | Basophils | 5 | 2018 | 15 | 0.390 |
Why?
| | Receptors, Adrenergic, beta-2 | 4 | 2012 | 16 | 0.390 |
Why?
| | Prevalence | 9 | 2019 | 1016 | 0.380 |
Why?
| | Poverty | 2 | 2012 | 218 | 0.370 |
Why?
| | Gastrointestinal Tract | 2 | 2011 | 110 | 0.360 |
Why?
| | Epitopes | 5 | 2025 | 62 | 0.340 |
Why?
| | Young Adult | 14 | 2022 | 4346 | 0.330 |
Why?
| | Family | 1 | 2011 | 170 | 0.330 |
Why?
| | Epidermal Growth Factor | 3 | 2005 | 37 | 0.320 |
Why?
| | Antibodies, Monoclonal | 2 | 2011 | 475 | 0.320 |
Why?
| | Parents | 2 | 2011 | 339 | 0.320 |
Why?
| | Education, Nursing, Continuing | 1 | 2010 | 20 | 0.320 |
Why?
| | Cytokines | 6 | 2021 | 622 | 0.320 |
Why?
| | Down-Regulation | 3 | 2012 | 348 | 0.320 |
Why?
| | Cross-Sectional Studies | 6 | 2019 | 1677 | 0.320 |
Why?
| | United States | 22 | 2024 | 5215 | 0.320 |
Why?
| | Nurse's Role | 1 | 2010 | 69 | 0.320 |
Why?
| | Urban Population | 2 | 2010 | 161 | 0.300 |
Why?
| | Mouth | 1 | 2009 | 33 | 0.300 |
Why?
| | Clinical Competence | 3 | 2013 | 405 | 0.300 |
Why?
| | Biomedical Research | 2 | 2018 | 260 | 0.280 |
Why?
| | Rural Health | 1 | 2008 | 85 | 0.280 |
Why?
| | Lung | 3 | 2019 | 479 | 0.280 |
Why?
| | Air Pollution, Indoor | 1 | 2008 | 27 | 0.280 |
Why?
| | Sympathomimetics | 3 | 2016 | 21 | 0.270 |
Why?
| | Adrenergic beta-Agonists | 3 | 2015 | 39 | 0.270 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2019 | 165 | 0.260 |
Why?
| | Animals | 16 | 2024 | 13485 | 0.260 |
Why?
| | Immunologic Factors | 3 | 2022 | 114 | 0.250 |
Why?
| | Amino Acids | 2 | 2025 | 386 | 0.250 |
Why?
| | Signal Transduction | 3 | 2005 | 1724 | 0.250 |
Why?
| | Anti-Infective Agents | 1 | 2007 | 106 | 0.250 |
Why?
| | Immunization | 5 | 2019 | 69 | 0.250 |
Why?
| | Wound Healing | 2 | 2005 | 223 | 0.250 |
Why?
| | Case Management | 1 | 2006 | 43 | 0.250 |
Why?
| | Phenotype | 3 | 2018 | 792 | 0.250 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2010 | 504 | 0.240 |
Why?
| | Anti-Allergic Agents | 2 | 2024 | 14 | 0.240 |
Why?
| | Cost of Illness | 1 | 2006 | 120 | 0.240 |
Why?
| | Population Surveillance | 1 | 2006 | 167 | 0.230 |
Why?
| | Fear | 1 | 2006 | 84 | 0.230 |
Why?
| | Administration, Sublingual | 4 | 2014 | 17 | 0.230 |
Why?
| | Life Style | 1 | 2006 | 148 | 0.230 |
Why?
| | Prospective Studies | 7 | 2020 | 2433 | 0.230 |
Why?
| | Bile Acids and Salts | 1 | 2025 | 81 | 0.230 |
Why?
| | Mycoses | 1 | 2006 | 152 | 0.220 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2024 | 230 | 0.220 |
Why?
| | Severity of Illness Index | 5 | 2012 | 1045 | 0.220 |
Why?
| | Quality of Life | 2 | 2021 | 893 | 0.210 |
Why?
| | Nutritional Status | 2 | 2023 | 146 | 0.210 |
Why?
| | Body Mass Index | 1 | 2007 | 701 | 0.210 |
Why?
| | Apoptosis | 1 | 2009 | 1120 | 0.210 |
Why?
| | Medicine, Chinese Traditional | 2 | 2015 | 6 | 0.200 |
Why?
| | Age Factors | 4 | 2020 | 1120 | 0.200 |
Why?
| | Dietetics | 3 | 2017 | 11 | 0.200 |
Why?
| | Cell Movement | 1 | 2004 | 271 | 0.200 |
Why?
| | Agricultural Workers' Diseases | 1 | 2003 | 4 | 0.200 |
Why?
| | Aircraft | 1 | 2003 | 8 | 0.200 |
Why?
| | Antifungal Agents | 1 | 2006 | 347 | 0.200 |
Why?
| | Leukocytes, Mononuclear | 4 | 2017 | 122 | 0.200 |
Why?
| | Candy | 1 | 2002 | 3 | 0.200 |
Why?
| | Pesticides | 1 | 2003 | 21 | 0.200 |
Why?
| | Th2 Cells | 2 | 2022 | 21 | 0.190 |
Why?
| | T-Lymphocyte Subsets | 2 | 2023 | 40 | 0.190 |
Why?
| | Spirometry | 2 | 2018 | 34 | 0.190 |
Why?
| | Dust | 2 | 2014 | 24 | 0.180 |
Why?
| | Diet | 2 | 2017 | 591 | 0.180 |
Why?
| | Occupational Exposure | 1 | 2003 | 111 | 0.180 |
Why?
| | Carbachol | 2 | 2019 | 27 | 0.180 |
Why?
| | Toll-Like Receptor 8 | 1 | 2021 | 3 | 0.180 |
Why?
| | Respiratory Hypersensitivity | 2 | 2019 | 17 | 0.180 |
Why?
| | T-Lymphocytes | 3 | 2021 | 318 | 0.180 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2021 | 18 | 0.170 |
Why?
| | Mosaicism | 1 | 2021 | 17 | 0.170 |
Why?
| | Longitudinal Studies | 3 | 2023 | 756 | 0.170 |
Why?
| | Pancytopenia | 1 | 2021 | 37 | 0.170 |
Why?
| | Health Promotion | 1 | 2023 | 271 | 0.170 |
Why?
| | Clinical Trials as Topic | 3 | 2022 | 461 | 0.170 |
Why?
| | Immunity, Mucosal | 2 | 2010 | 16 | 0.160 |
Why?
| | Middle Aged | 10 | 2022 | 13133 | 0.160 |
Why?
| | Bronchodilator Agents | 2 | 2019 | 72 | 0.160 |
Why?
| | Needs Assessment | 2 | 2010 | 141 | 0.150 |
Why?
| | Tertiary Healthcare | 1 | 2019 | 15 | 0.150 |
Why?
| | Isoproterenol | 2 | 2012 | 56 | 0.150 |
Why?
| | Bronchoconstriction | 1 | 2019 | 6 | 0.150 |
Why?
| | Hypersensitivity, Immediate | 3 | 2024 | 15 | 0.150 |
Why?
| | Population Groups | 1 | 2018 | 8 | 0.150 |
Why?
| | Acetazolamide | 1 | 2018 | 16 | 0.140 |
Why?
| | Pseudotumor Cerebri | 1 | 2018 | 23 | 0.140 |
Why?
| | Drug Hypersensitivity | 1 | 2018 | 42 | 0.140 |
Why?
| | Cells, Cultured | 5 | 2015 | 1583 | 0.140 |
Why?
| | Picornaviridae Infections | 1 | 2018 | 22 | 0.140 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2025 | 114 | 0.140 |
Why?
| | Epithelial Cells | 3 | 2019 | 217 | 0.140 |
Why?
| | Models, Biological | 2 | 2019 | 735 | 0.140 |
Why?
| | Prognosis | 5 | 2021 | 2100 | 0.130 |
Why?
| | Granulocytes | 1 | 2017 | 27 | 0.130 |
Why?
| | Protein Transport | 2 | 2012 | 172 | 0.130 |
Why?
| | Feces | 3 | 2025 | 159 | 0.130 |
Why?
| | Particulate Matter | 1 | 2017 | 70 | 0.130 |
Why?
| | Seasons | 1 | 2017 | 95 | 0.130 |
Why?
| | Anticonvulsants | 1 | 2018 | 136 | 0.130 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 32 | 0.130 |
Why?
| | Inflammation | 1 | 2021 | 649 | 0.130 |
Why?
| | Nut Hypersensitivity | 2 | 2015 | 3 | 0.130 |
Why?
| | Primary Prevention | 1 | 2017 | 46 | 0.130 |
Why?
| | Proton Pump Inhibitors | 1 | 2017 | 94 | 0.130 |
Why?
| | Treatment Failure | 3 | 2025 | 117 | 0.120 |
Why?
| | Acetaminophen | 1 | 2019 | 272 | 0.120 |
Why?
| | Respiratory Function Tests | 2 | 2008 | 90 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 271 | 0.120 |
Why?
| | Drugs, Chinese Herbal | 1 | 2015 | 9 | 0.120 |
Why?
| | Basophil Degranulation Test | 1 | 2015 | 3 | 0.120 |
Why?
| | Milk Proteins | 3 | 2024 | 77 | 0.120 |
Why?
| | Therapies, Investigational | 1 | 2015 | 3 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2018 | 317 | 0.110 |
Why?
| | Microscopy, Fluorescence | 2 | 2008 | 140 | 0.110 |
Why?
| | Cell Differentiation | 3 | 2021 | 667 | 0.110 |
Why?
| | Patient Compliance | 1 | 2016 | 228 | 0.110 |
Why?
| | Guideline Adherence | 2 | 2016 | 142 | 0.110 |
Why?
| | Advisory Committees | 1 | 2014 | 74 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2018 | 625 | 0.110 |
Why?
| | Adrenal Cortex Hormones | 2 | 2024 | 116 | 0.110 |
Why?
| | Meningitis, Pneumococcal | 1 | 2013 | 7 | 0.100 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2013 | 10 | 0.100 |
Why?
| | Patient Selection | 1 | 2015 | 269 | 0.100 |
Why?
| | Manikins | 1 | 2013 | 32 | 0.100 |
Why?
| | Mycobacterium fortuitum | 1 | 2013 | 6 | 0.100 |
Why?
| | Emergency Medicine | 1 | 2013 | 50 | 0.100 |
Why?
| | Macrolides | 1 | 2013 | 17 | 0.100 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2013 | 63 | 0.100 |
Why?
| | Pediatrics | 2 | 2013 | 302 | 0.100 |
Why?
| | Clarithromycin | 1 | 2013 | 42 | 0.100 |
Why?
| | Sesamum | 1 | 2012 | 1 | 0.100 |
Why?
| | Plant Extracts | 1 | 2015 | 199 | 0.100 |
Why?
| | Cohort Studies | 4 | 2020 | 1576 | 0.100 |
Why?
| | Methicillin | 1 | 2012 | 10 | 0.090 |
Why?
| | Clindamycin | 1 | 2012 | 14 | 0.090 |
Why?
| | Research | 1 | 2013 | 109 | 0.090 |
Why?
| | Medicaid | 2 | 2006 | 264 | 0.090 |
Why?
| | House Calls | 1 | 2012 | 26 | 0.090 |
Why?
| | Chickens | 2 | 2021 | 107 | 0.090 |
Why?
| | Drug Resistance, Bacterial | 1 | 2012 | 75 | 0.090 |
Why?
| | Telemedicine | 1 | 2018 | 490 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1099 | 0.090 |
Why?
| | Cyclic AMP | 3 | 2012 | 90 | 0.090 |
Why?
| | Morbidity | 1 | 2012 | 137 | 0.090 |
Why?
| | Influenza Vaccines | 1 | 2011 | 36 | 0.090 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2011 | 23 | 0.090 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 184 | 0.090 |
Why?
| | Powders | 2 | 2021 | 25 | 0.090 |
Why?
| | Exercise | 1 | 2015 | 559 | 0.080 |
Why?
| | Food | 1 | 2010 | 67 | 0.080 |
Why?
| | Risk Assessment | 2 | 2017 | 1349 | 0.080 |
Why?
| | Child Nutrition Sciences | 1 | 2010 | 10 | 0.080 |
Why?
| | Influenza, Human | 1 | 2011 | 90 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2024 | 1202 | 0.080 |
Why?
| | Clinical Protocols | 1 | 2010 | 106 | 0.080 |
Why?
| | Specialization | 1 | 2010 | 48 | 0.080 |
Why?
| | Maternal Exposure | 1 | 2010 | 96 | 0.080 |
Why?
| | Retrospective Studies | 6 | 2016 | 6694 | 0.080 |
Why?
| | Algorithms | 2 | 2020 | 673 | 0.080 |
Why?
| | Time Factors | 1 | 2016 | 2987 | 0.080 |
Why?
| | Nutrition Surveys | 1 | 2010 | 119 | 0.080 |
Why?
| | Caregivers | 1 | 2012 | 239 | 0.080 |
Why?
| | Cooking | 2 | 2020 | 16 | 0.080 |
Why?
| | Microarray Analysis | 1 | 2009 | 69 | 0.080 |
Why?
| | Staphylococcal Infections | 1 | 2012 | 270 | 0.080 |
Why?
| | Program Development | 1 | 2010 | 164 | 0.080 |
Why?
| | Gene Expression | 2 | 2019 | 618 | 0.080 |
Why?
| | Staphylococcus aureus | 1 | 2012 | 312 | 0.080 |
Why?
| | Ovum | 2 | 2019 | 7 | 0.070 |
Why?
| | Program Evaluation | 1 | 2010 | 351 | 0.070 |
Why?
| | Respiratory Mechanics | 1 | 2008 | 36 | 0.070 |
Why?
| | Arachidonic Acid | 1 | 2008 | 34 | 0.070 |
Why?
| | Anti-Asthmatic Agents | 2 | 2006 | 33 | 0.070 |
Why?
| | Recurrence | 2 | 2010 | 680 | 0.070 |
Why?
| | Docosahexaenoic Acids | 1 | 2008 | 31 | 0.070 |
Why?
| | 2S Albumins, Plant | 2 | 2020 | 7 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 199 | 0.070 |
Why?
| | Antibodies | 1 | 2008 | 144 | 0.070 |
Why?
| | Health Surveys | 2 | 2012 | 238 | 0.070 |
Why?
| | Meta-Analysis as Topic | 1 | 2007 | 39 | 0.070 |
Why?
| | Luminescent Proteins | 2 | 2005 | 47 | 0.070 |
Why?
| | Health Status Indicators | 1 | 2007 | 81 | 0.070 |
Why?
| | Infant, Newborn | 4 | 2019 | 2871 | 0.060 |
Why?
| | Agammaglobulinemia | 1 | 2006 | 9 | 0.060 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2006 | 8 | 0.060 |
Why?
| | Urban Health | 1 | 2006 | 31 | 0.060 |
Why?
| | Acute Disease | 1 | 2007 | 384 | 0.060 |
Why?
| | Infant Formula | 1 | 2008 | 154 | 0.060 |
Why?
| | Nasal Polyps | 1 | 2006 | 4 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 816 | 0.060 |
Why?
| | Consensus | 2 | 2017 | 195 | 0.060 |
Why?
| | Bronchi | 1 | 2005 | 41 | 0.060 |
Why?
| | Odds Ratio | 2 | 2019 | 563 | 0.060 |
Why?
| | Antibody Specificity | 2 | 2017 | 36 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 2 | 2005 | 177 | 0.060 |
Why?
| | Spine | 1 | 2006 | 86 | 0.060 |
Why?
| | Metagenomics | 1 | 2025 | 36 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 938 | 0.060 |
Why?
| | Pilot Projects | 1 | 2007 | 725 | 0.060 |
Why?
| | Societies, Scientific | 2 | 2017 | 14 | 0.050 |
Why?
| | Osteoporosis | 1 | 2006 | 157 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2003 | 576 | 0.050 |
Why?
| | Blood Proteins | 1 | 2004 | 84 | 0.050 |
Why?
| | Albuterol | 2 | 2019 | 54 | 0.050 |
Why?
| | Molecular Sequence Data | 2 | 2003 | 778 | 0.050 |
Why?
| | Tobacco Smoke Pollution | 1 | 2004 | 50 | 0.050 |
Why?
| | Adenoviridae | 1 | 2003 | 46 | 0.050 |
Why?
| | Gene Transfer Techniques | 1 | 2003 | 44 | 0.050 |
Why?
| | Sex Factors | 1 | 2006 | 735 | 0.050 |
Why?
| | Cattle | 1 | 2024 | 197 | 0.050 |
Why?
| | Green Fluorescent Proteins | 1 | 2003 | 85 | 0.050 |
Why?
| | Bone Density | 1 | 2006 | 396 | 0.050 |
Why?
| | Butyrates | 1 | 2023 | 30 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2003 | 128 | 0.050 |
Why?
| | Antigens | 1 | 2023 | 41 | 0.050 |
Why?
| | Receptors, Vasopressin | 1 | 2003 | 23 | 0.050 |
Why?
| | Inhalation Spacers | 1 | 2002 | 6 | 0.050 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2002 | 9 | 0.050 |
Why?
| | Food Additives | 1 | 2002 | 7 | 0.050 |
Why?
| | Gelatin | 1 | 2002 | 22 | 0.050 |
Why?
| | Immunoglobulin A | 1 | 2022 | 46 | 0.050 |
Why?
| | Metabolome | 1 | 2023 | 100 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2022 | 69 | 0.050 |
Why?
| | Fibroblasts | 1 | 2004 | 357 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2003 | 490 | 0.050 |
Why?
| | Pituitary Gland | 1 | 2003 | 87 | 0.050 |
Why?
| | Protein Sorting Signals | 1 | 2002 | 7 | 0.050 |
Why?
| | Emollients | 1 | 2021 | 2 | 0.050 |
Why?
| | Emergency Service, Hospital | 1 | 2006 | 521 | 0.050 |
Why?
| | Amino Acid Motifs | 1 | 2002 | 59 | 0.050 |
Why?
| | Socioeconomic Factors | 1 | 2004 | 609 | 0.050 |
Why?
| | Ovomucin | 1 | 2021 | 1 | 0.050 |
Why?
| | Vitellogenins | 1 | 2021 | 2 | 0.050 |
Why?
| | Ovalbumin | 1 | 2021 | 19 | 0.050 |
Why?
| | Genes, Reporter | 1 | 2002 | 86 | 0.050 |
Why?
| | Sequence Alignment | 1 | 2002 | 121 | 0.050 |
Why?
| | Endocytosis | 1 | 2002 | 52 | 0.050 |
Why?
| | Hyperplasia | 1 | 2021 | 96 | 0.040 |
Why?
| | Lysosomes | 1 | 2002 | 65 | 0.040 |
Why?
| | Pedigree | 1 | 2021 | 126 | 0.040 |
Why?
| | Injections, Subcutaneous | 1 | 2020 | 54 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2021 | 161 | 0.040 |
Why?
| | Peptides | 1 | 2021 | 239 | 0.040 |
Why?
| | Phylogeny | 2 | 2016 | 229 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2021 | 178 | 0.040 |
Why?
| | Diet Therapy | 1 | 2019 | 8 | 0.040 |
Why?
| | Milk | 2 | 2012 | 84 | 0.040 |
Why?
| | Kidney | 1 | 2004 | 716 | 0.040 |
Why?
| | Immunity | 1 | 2019 | 35 | 0.040 |
Why?
| | Age of Onset | 2 | 2012 | 109 | 0.040 |
Why?
| | Tissue Array Analysis | 1 | 2019 | 45 | 0.040 |
Why?
| | Cell Line | 1 | 2002 | 1020 | 0.040 |
Why?
| | Muscle, Smooth | 1 | 2019 | 63 | 0.040 |
Why?
| | Egg Proteins, Dietary | 1 | 2018 | 2 | 0.040 |
Why?
| | Government Programs | 1 | 2018 | 16 | 0.040 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2018 | 13 | 0.040 |
Why?
| | Organ Culture Techniques | 1 | 2019 | 47 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2019 | 112 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2019 | 158 | 0.040 |
Why?
| | ROC Curve | 1 | 2019 | 249 | 0.040 |
Why?
| | Mice, Inbred Strains | 1 | 2019 | 165 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2019 | 116 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2019 | 136 | 0.040 |
Why?
| | Eating | 1 | 2019 | 158 | 0.040 |
Why?
| | Rhinovirus | 1 | 2018 | 24 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 83 | 0.030 |
Why?
| | Endoscopy | 1 | 2018 | 126 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 126 | 0.030 |
Why?
| | Skin Irritancy Tests | 1 | 2017 | 3 | 0.030 |
Why?
| | Blood Cells | 1 | 2017 | 37 | 0.030 |
Why?
| | Community Health Services | 1 | 2018 | 102 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2017 | 112 | 0.030 |
Why?
| | Staining and Labeling | 1 | 2017 | 92 | 0.030 |
Why?
| | Quality Assurance, Health Care | 1 | 2018 | 147 | 0.030 |
Why?
| | Specimen Handling | 1 | 2017 | 59 | 0.030 |
Why?
| | Transcriptome | 1 | 2019 | 357 | 0.030 |
Why?
| | Eczema | 1 | 2017 | 12 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2016 | 28 | 0.030 |
Why?
| | Nutritional Sciences | 1 | 2017 | 37 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 870 | 0.030 |
Why?
| | Histamine Antagonists | 1 | 2016 | 17 | 0.030 |
Why?
| | Models, Statistical | 1 | 2018 | 230 | 0.030 |
Why?
| | Risk Reduction Behavior | 1 | 2017 | 58 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2017 | 120 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 2016 | 57 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2019 | 396 | 0.030 |
Why?
| | Quality Improvement | 1 | 2018 | 226 | 0.030 |
Why?
| | DNA Methylation | 1 | 2019 | 573 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2017 | 396 | 0.030 |
Why?
| | Risk | 1 | 2016 | 315 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 1365 | 0.030 |
Why?
| | Interleukin-5 | 1 | 2015 | 6 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 598 | 0.030 |
Why?
| | Emergency Medical Services | 1 | 2016 | 123 | 0.030 |
Why?
| | Placebos | 1 | 2015 | 83 | 0.030 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2015 | 21 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2015 | 81 | 0.030 |
Why?
| | Housing | 1 | 2014 | 48 | 0.030 |
Why?
| | Bacteria | 1 | 2016 | 223 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2019 | 805 | 0.030 |
Why?
| | Medication Adherence | 1 | 2015 | 133 | 0.030 |
Why?
| | Emergency Treatment | 1 | 2013 | 29 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 1888 | 0.030 |
Why?
| | Antibiotic Prophylaxis | 1 | 2013 | 63 | 0.030 |
Why?
| | Amikacin | 1 | 2013 | 17 | 0.030 |
Why?
| | Glycoproteins | 1 | 2013 | 123 | 0.030 |
Why?
| | Azithromycin | 1 | 2013 | 25 | 0.030 |
Why?
| | Antibody Affinity | 1 | 2012 | 9 | 0.020 |
Why?
| | Urticaria | 1 | 2013 | 19 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 637 | 0.020 |
Why?
| | Trees | 1 | 2012 | 18 | 0.020 |
Why?
| | Incidence | 2 | 2006 | 1096 | 0.020 |
Why?
| | Eggs | 1 | 2012 | 8 | 0.020 |
Why?
| | Equipment Design | 1 | 2013 | 287 | 0.020 |
Why?
| | Poisson Distribution | 1 | 2012 | 37 | 0.020 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2012 | 5 | 0.020 |
Why?
| | Hospitals, University | 1 | 2012 | 73 | 0.020 |
Why?
| | Rats | 2 | 2008 | 3228 | 0.020 |
Why?
| | rab GTP-Binding Proteins | 1 | 2012 | 23 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2012 | 127 | 0.020 |
Why?
| | Patient Care Team | 1 | 2013 | 267 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2013 | 344 | 0.020 |
Why?
| | Regression Analysis | 1 | 2012 | 400 | 0.020 |
Why?
| | Food Labeling | 1 | 2011 | 5 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2012 | 236 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2012 | 271 | 0.020 |
Why?
| | Hospitals, Pediatric | 1 | 2012 | 241 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 41 | 0.020 |
Why?
| | Bronchitis | 1 | 2010 | 9 | 0.020 |
Why?
| | Demography | 1 | 2010 | 92 | 0.020 |
Why?
| | Intestinal Mucosa | 1 | 2011 | 228 | 0.020 |
Why?
| | Diphenhydramine | 1 | 2009 | 19 | 0.020 |
Why?
| | Self Efficacy | 1 | 2010 | 133 | 0.020 |
Why?
| | Oscillometry | 1 | 2008 | 7 | 0.020 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2008 | 20 | 0.020 |
Why?
| | Infant Food | 1 | 2008 | 28 | 0.020 |
Why?
| | Growth | 1 | 2008 | 40 | 0.020 |
Why?
| | Internet | 1 | 2010 | 262 | 0.020 |
Why?
| | Computer Simulation | 1 | 2008 | 285 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2008 | 116 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2010 | 1028 | 0.020 |
Why?
| | Reference Standards | 1 | 2006 | 51 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2006 | 106 | 0.010 |
Why?
| | Cause of Death | 1 | 2006 | 157 | 0.010 |
Why?
| | Drug Combinations | 1 | 2005 | 136 | 0.010 |
Why?
| | Absorptiometry, Photon | 1 | 2006 | 161 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2005 | 152 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2008 | 1558 | 0.010 |
Why?
| | Aged | 1 | 2018 | 10242 | 0.010 |
Why?
| | Dietary Supplements | 1 | 2008 | 470 | 0.010 |
Why?
| | Pregnancy | 1 | 2010 | 2642 | 0.010 |
Why?
| | Sequence Homology | 1 | 2003 | 16 | 0.010 |
Why?
| | Second Messenger Systems | 1 | 2003 | 14 | 0.010 |
Why?
| | Phosphatidylinositols | 1 | 2003 | 17 | 0.010 |
Why?
| | Aging | 1 | 2008 | 722 | 0.010 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2003 | 35 | 0.010 |
Why?
| | COS Cells | 1 | 2003 | 76 | 0.010 |
Why?
| | Durable Medical Equipment | 1 | 2002 | 2 | 0.010 |
Why?
| | Registries | 1 | 2006 | 638 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2003 | 181 | 0.010 |
Why?
| | Reimbursement Mechanisms | 1 | 2002 | 24 | 0.010 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2002 | 25 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2005 | 347 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 632 | 0.010 |
Why?
| | Pharmacies | 1 | 2002 | 61 | 0.010 |
Why?
| | Calcium | 1 | 2003 | 396 | 0.010 |
Why?
|
|
Jones's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|